Cardiovascular
Mitral Regurgitation
25
Pipeline Programs↗
10
Active Trials↗
14
Companies Involved↗
Mitral regurgitation is an emerging landscape with 25 programs across 14 companies. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), AstraZeneca, Novartis. 5 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 22
Phase 33
Analysis
Trial Status
25
clinical trials
Recruiting8 · 32%
Completed6 · 24%
Unknown status4 · 16%
Terminated3 · 12%
Not yet recruiting2 · 8%
Withdrawn2 · 8%
Clinical Trials
Trial Activity
25 trials
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
Recruiting·—·N/A·NCT06883864·146 enrolled
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
Recruiting·—·N/A·NCT07379788·180 enrolled
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR Transfemoral System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Recruiting·—·Preclinical·NCT05496998·400 enrolled
Anchord Mitral Chordal Repair System for Patients With Degenerative Mitral Regurgitation
Not yet recruiting·—·Preclinical·NCT07671820·5 enrolled
Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
Completed·—·Phase 4·NCT02687932·118 enrolled
Ertugliflozin for Functional Mitral Regurgitation
Completed·—·Phase 3·NCT04231331·128 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)